The Cancer DepMap (https://depmap.org/) shows significant correlation between functional dependence of cancer cell lines with loss of NF1 and loss of NF2 (Pearson correlation 0.23, slope=0.42, p = 4.22 × 10−14), but published screens with the MEK inhibitor trametinib suggest mixed results for sgRNAs targeting NF2 in pancreatic or lung cancer cells45. This evidence concerns the gene MAP2K7 and lung carcinoma.